NYSDOH CLEP Laboratory Developed Test Compliance — Frequently Asked Questions
Last updated: April 2026
Last updated: April 2026
12 expert answers on NYSDOH CLEP LDT compliance — who needs approval, CLIA vs. CLEP differences, FDA LDT rule impact, out-of-state lab requirements, tiered risk classification, and the consulting process. For an overview of IHS's CLEP consulting services, see our NYSDOH CLEP LDT service page.
Data transparency note: NYSDOH does not publish ranked quantitative deficiency or RFI statistics. Where specific data is unavailable, this page states that explicitly rather than estimating.
Frequently Asked Questions
What is the NYSDOH Clinical Laboratory Evaluation Program (CLEP)?
CLEP, administered by the NYSDOH Wadsworth Center, is the only U.S. regulatory program that mandates formal pre-market review and approval of Laboratory Developed Tests. Unlike CLIA, which governs laboratory operations, CLEP requires technical review of each individual LDT methodology — including clinical validity proof — before laboratories may report results on New York specimens. The program has processed over 15,000 LDT applications since 1991 (NYSDOH Wadsworth Center). As of 2025, approximately 1,146 facilities hold CLEP approvals covering approximately 10,977 approved LDTs (NYSDOH Approved LDT Registry).
What is a Laboratory Developed Test (LDT) and why does New York require separate approval?
An LDT is a test designed, validated, and used within a single laboratory — distinct from commercially manufactured test kits with FDA clearance. New York has required pre-market LDT review since 1991, recognizing that patient harm from inaccurate diagnostics was a public health concern that federal CLIA oversight did not fully address. CLEP's clinical validity requirement — demanding literature or trial data proving a test performs as claimed — goes substantially beyond CLIA. This higher bar is why CLEP approval became the national LDT quality standard, especially after the 2025 vacatur of the FDA's LDT rule eliminated federal premarket oversight.
Does my laboratory need NYSDOH CLEP approval if it is located outside New York?
Yes. Any laboratory performing LDTs on specimens from New York residents must hold a valid NYSDOH permit with CLEP-approved LDTs — regardless of physical location. 77% of CLEP submissions originate from outside New York (Journal of Molecular Diagnostics 2025). CLIA certification does not satisfy this requirement. Out-of-state laboratories also pay all NYSDOH surveyor travel expenses for on-site inspections. The demand for CLEP consulting is national, not regional.
What is the difference between CLIA certification and NYSDOH CLEP approval?
CLIA (CMS) governs laboratory operations, personnel qualifications, and quality systems — but does not review individual test methodologies. NYSDOH CLEP mandates pre-market technical review of each individual LDT, including clinical validity proof that CLIA does not require. CLIA is necessary but not sufficient for testing New York specimens. A laboratory with a valid CLIA certificate that lacks NYSDOH CLEP approval for its LDTs is operating unlawfully with respect to New York specimens. CAP accreditation similarly does not satisfy CLEP requirements — see the CAP question below.
What documentation is required to apply for NYSDOH LDT approval?
Required documentation: SOPs for all pre-analytic, analytic, and post-analytic processes; Method Validation Data (precision, accuracy, reproducibility, Limit of Detection, analytical specificity, clinical validity data); Risk Attestation Form; category-specific checklist (Molecular, Oncology, Toxicology, Trace Elements, Microbiology, or General); NY State Certificate of Qualification (CQ) for the Lab Director in the exact testing categories; Facility Personnel Form via Health Commerce System (HCS); proficiency testing provider authorization to release results to NYSDOH; and QMS documentation including CAPA records. For NGS panels, bioinformatics pipeline documentation and variant classification methodology are additionally required.
How long does the NYSDOH CLEP LDT review process take?
12 to 14 months from gap assessment to full permit issuance for initial applicants. Existing permitted labs adding new categories: 6 to 9 months. Key milestones: Lab Director CQ processing (2–4 months, NYSDOH-controlled, cannot be accelerated); documentation build (months 1–4); risk tier assignment after submission (3–6 weeks); RFI response if required — 54% of applications receive at least one RFI (Journal of Molecular Diagnostics 2025) — up to 60 days; on-site survey; permit issuance. Annual permit cycle: July 1–June 30; annual reapplication opens March 28, due April 28.
What are the most common reasons NYSDOH CLEP LDT applications receive RFIs?
54% of applications require at least one RFI (Journal of Molecular Diagnostics 2025). Note: NYSDOH does not publish ranked RFI statistics; the following is derived from regulatory document analysis and IHS consulting experience. Common triggers: insufficient clinical validity documentation; method validation data gaps; Risk Attestation Form responses inconsistent with validation data; SOPs lacking sufficient operational detail; Designated Person documentation format issues. The 60-day response window is firm — a missed deadline causes automatic application inactivation, losing all work to that point.
How does the 2024 FDA LDT Final Rule and its vacatur affect NYSDOH CLEP requirements?
Three events: (1) May 2024 — FDA issued final rule to regulate LDTs as medical devices; explicitly exempted CLEP-approved tests from premarket review, triggering a surge in CLEP applications. (2) March 31, 2025 — U.S. District Court (Eastern District of Texas) vacated the FDA rule; FDA chose not to appeal (FDA). (3) September 19, 2025 — FDA reverted regulatory text to pre-May 2024 status (FDA). Net result: CLEP is now the only rigorous pre-market LDT review framework operating in the U.S. Payers and institutional partners increasingly treat CLEP approval as the national LDT quality standard, accelerating reimbursement from Medicare MACs and commercial insurers.
What does a NYSDOH CLEP inspection assess?
CLEP surveyors assess: QMS implementation on bench (internal audit records, CAPA documentation, deviation logs); Lab Director documented on-site presence; personnel competency documentation and proficiency testing participation; actual testing process observation; environmental safety; equipment calibration and maintenance records; specimen handling and result reporting procedures; and record retention compliance. Out-of-state labs pay all NYSDOH surveyor travel expenses. Inspections are scheduled only after all documentation deficiencies are resolved.
What are the consequences of testing New York specimens without CLEP approval?
Testing New York specimens without a valid NYSDOH permit and CLEP-approved LDTs is unlawful under New York Public Health Law. Consequences: cease-testing orders; civil penalties; permit denial or revocation; exclusion from New York Medicaid reimbursement. Laboratories that discover they have been testing New York specimens without approval should seek consulting guidance immediately. A remediation pathway exists — NYSDOH's process allows for retroactive compliance — but requires prompt, well-documented action to minimize the enforcement window.
What is the NYSDOH tiered risk classification system for LDT submissions?
NYSDOH assigns each LDT to a risk tier after reviewing the Risk Attestation Form: Low Risk — ~34% of submissions receive immediate full approval (Journal of Molecular Diagnostics 2025); Moderate Risk — conditional approval, lab may bill while state review continues; High Risk — full technical review required before any approval (most NGS oncology panels, companion diagnostics, novel molecular assays); Clinical Trial Category — tests used exclusively in FDA-regulated trials; Exempt — tests meeting specific exemption criteria. IHS helps organizations complete the Risk Attestation Form accurately while supporting the most favorable tier assignment the data supports.
Does CAP accreditation satisfy NYSDOH CLEP requirements?
No. CAP and NYSDOH CLEP are independent frameworks with separate applications, fees, and inspection authorities. A CAP-accredited laboratory still requires a separate NYSDOH permit and individual CLEP approval for each LDT performed on New York specimens. CAP accreditation may support favorable documentation review as evidence of quality systems maturity — but it does not substitute for CLEP's pre-market LDT review. The same applies to CLIA certification. Both are necessary; neither is sufficient for testing New York specimens without CLEP approval.
Ready to Pursue NYSDOH CLEP Approval?
Schedule a gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your laboratory's current compliance posture and give you a clear roadmap to permit issuance — including Lab Director CQ planning, documentation requirements, and RFI risk mitigation strategy.